REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented ...

Core Insights - Biotricity Inc. has been recognized as one of The Americas' Fastest-Growing Companies 2025 by the Financial Times, achieving a remarkable growth rate of 256.4% during challenging global conditions [1][2][4] Company Performance - The evaluation by the Financial Times, in collaboration with Statista, focused on independent companies across the Americas based on revenue growth from 2020 to 2023, amidst significant economic challenges such as the COVID-19 pandemic and supply chain disruptions [2] - Biotricity's growth is attributed to the increasing demand for smart remote monitoring solutions, addressing the healthcare accessibility issues faced by over 100 million Americans [3] Industry Context - The healthcare industry is experiencing a transformation with a heightened need for remote monitoring services, particularly for high-risk cardiac patients, which Biotricity is addressing through its proprietary technologies [3] - The recognition from the Financial Times serves as validation for Biotricity's innovative approach in chronic care management, especially in the cardiac sector [4]

Biotricity’s latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), (“Biotricity” or the “Company”), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its i ...

Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ("Biotricity" or the "Company"), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2025 BIOTRICITY INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) Nevada 001-40761 30-0983531 (IRS Employer Identification No.) 203 Redwood Shores Parkway, Suite 600 Redwood City, Califo ...

Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to ...

Financial Performance - Total revenue for the three months ended December 31, 2024, was $3,619,108, representing a 21.7% increase from $2,972,972 in the same period of 2023[11] - Gross profit for the nine months ended December 31, 2024, reached $7,586,310, up 24.7% from $6,083,968 in the prior year[11] - The company reported a comprehensive loss of $1,241,866 for the three months ended December 31, 2024, compared to a loss of $3,250,496 in the same period of 2023[11] - For the nine months ended December 31, 2024, Biotricity reported a net loss of $6,485,442, an improvement from a net loss of $9,911,813 for the same period in 2023, representing a 34.5% reduction in losses[16] - Total revenue for the nine months ended December 31, 2024, was $10,087,697, a 13.5% increase compared to $8,885,034 for the same period in 2023[38] Expenses and Liabilities - Operating expenses decreased to $2,932,950 for the three months ended December 31, 2024, down 15% from $3,449,760 in the same quarter of 2023[11] - Research and development expenses for the nine months ended December 31, 2024, totaled $1,583,093, a decrease from $1,863,551 in the previous year[11] - Total liabilities decreased slightly to $35,783,372 as of December 31, 2024, from $35,919,442 as of March 31, 2024[10] - The company had an accumulated deficit of $137,419,652 and a working capital deficiency of $16,280,084 as of December 31, 2024, raising concerns about its ability to continue as a going concern[26] Equity and Shares - The weighted average number of common shares outstanding increased to 24,232,369 for the three months ended December 31, 2024, compared to 8,979,430 in the same period of 2023[11] - The total shares to be issued increased to 24,555,114, indicating potential future equity dilution[12] - The company issued 70,000 common shares, resulting in an increase of $42,850 in additional paid-in capital[12] - A total of 30,000 shares were issued for services, which added $30,000 to the company's equity[12] - The company issued 1,524,719 warrants for private placement holders, contributing to additional paid-in capital[14] Cash and Assets - Cash reserves decreased to $509,601 as of December 31, 2024, down from $786,060 as of March 31, 2024[10] - Total current assets increased to $4,861,343 as of December 31, 2024, compared to $4,470,573 as of March 31, 2024[10] - Biotricity's inventory as of December 31, 2024, was valued at $1,570,085, down from $1,879,402 as of March 31, 2024[40] Debt and Financing - The Company issued $11,275,500 in Series A Convertible Promissory Notes, which accrue interest at 12% per annum[89] - The Series A Notes can be converted into common stock at a conversion price equal to 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date[91] - The Company recognized interest expense of $15,465 and $65,184 for the three and nine months ended December 31, 2024, respectively[132] - The Company entered into a short-term promissory note agreement resulting in gross proceeds of $600,000, with a fixed interest rate of 25% per annum[148] Stockholder's Deficit - As of December 31, 2023, the total stockholders' deficit was $27,756,354, reflecting a net loss before dividends of $2,808,091 for the period[14] - The balance of accumulated deficit as of December 31, 2024, is $137,419,652, which highlights ongoing financial difficulties[12] - Preferred stock dividends for the period amount to $89,392, contributing to the overall financial strain[12] Accounting and Valuation - The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options and warrants, considering inputs like volatility and risk-free rate[44][46] - The fair value of derivative liabilities is classified as Level 3 financial instruments, indicating reliance on unobservable inputs[63] - The calculation of current and deferred income taxes involves significant estimates and assumptions regarding future operating results and tax legislation[52] Management Outlook - Management anticipates continued revenue growth and loss reduction through business development and additional equity and debt capitalization[27] - The company plans to continue investing in capital expenditures and research and development for its product lines, including Bioflux, Biocore, and Biocare[32]

Core Insights - Biotricity Inc. reported strong financial results for the third quarter of fiscal 2025, with a revenue growth of 22% year-over-year, reaching $3.6 million, and an 11% increase sequentially from the previous quarter [5][6] - The company emphasized its commitment to innovation in healthcare technology, focusing on automation, operating efficiency, and financial discipline to drive revenue and margins [2][3] - Management indicated that the company achieved positive cash flow for Q3-FY25 on a current operating basis, and improvements in gross margins and operating results are expected as the company approaches profitability [5][6] Financial Performance - The company expects to report a revenue growth of 22% from the same quarter last year, amounting to $3.6 million, and an 11% increase from the previous quarter [5] - Biotricity is focused on recurring revenue growth and operational efficiencies, which have contributed to improved cash flow [5] - Full financial results will be disclosed on February 19, 2025, with a conference call scheduled for February 20, 2025, to discuss these results [3][5] Business Strategy - The company continues to leverage its Biocore suite of products and is dedicated to redefining medical diagnostics and patient care through innovative AI-driven solutions [2][3] - Biotricity aims to bridge the gap in remote monitoring and chronic care management, establishing a strong standard for preventive and personal care in the healthcare market [7]

Group 1 - The Purpose Bitcoin Yield ETF (TSX: BTCY:CA) is the first actively managed Bitcoin ETF, designed to provide investors with a monthly yield or distribution [1] - This ETF is traded on the Toronto Stock Exchange (TSX) and aims to offer a unique investment opportunity in the digital asset space [1] Group 2 - The article emphasizes the importance of understanding various investment strategies and asset classes, particularly in alternative investments [1] - The author has a strong background in market research, trend analysis, and portfolio management, focusing on maximizing investment returns while mitigating risks [1] - The motivation behind the article is to share data-driven analyses and foster a community of informed investors [1]

Core Insights - Biotricity Inc. and B-Secur have partnered to create an advanced, device-neutral platform for integrated heart monitoring, enhancing capabilities for healthcare providers and diagnostic facilities [1][2] - The partnership aims to address critical gaps in cardiac care delivery, improving accessibility and efficiency for both healthcare providers and patients [3][5] Company Overview - Biotricity is focused on reforming the healthcare market through remote monitoring and chronic care management, providing diagnostic solutions for chronic conditions [6] - B-Secur specializes in biosensing technology, offering medical-grade ECG data for faster diagnosis and management, and is ISO 13485:2016 certified [5] Industry Context - With 90% of U.S. adults at risk of cardiovascular disease (CVD) and a projected shortage of up to 124,000 physicians by 2034, there is an urgent need for scalable solutions for early detection and intervention [3] - The financial burden of CVD is expected to triple to $1.8 trillion by 2050, highlighting the importance of proactive cardiac management [3][4]